GSA Capital Partners LLP Has $178,000 Holdings in Hookipa Pharma Inc (NASDAQ:HOOK)

GSA Capital Partners LLP raised its holdings in shares of Hookipa Pharma Inc (NASDAQ:HOOKGet Rating) by 124.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,878 shares of the company’s stock after buying an additional 43,144 shares during the quarter. GSA Capital Partners LLP owned about 0.14% of Hookipa Pharma worth $178,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HOOK. Banque Cantonale Vaudoise bought a new stake in shares of Hookipa Pharma during the first quarter valued at approximately $46,000. Redmile Group LLC increased its position in shares of Hookipa Pharma by 29.3% during the fourth quarter. Redmile Group LLC now owns 2,385,136 shares of the company’s stock valued at $5,557,000 after purchasing an additional 540,831 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of Hookipa Pharma by 210.5% during the fourth quarter. Acadian Asset Management LLC now owns 252,256 shares of the company’s stock valued at $587,000 after purchasing an additional 171,019 shares during the period. 53.98% of the stock is currently owned by institutional investors and hedge funds.

Hookipa Pharma Price Performance

Hookipa Pharma stock opened at $1.40 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market cap of $76.59 million, a P/E ratio of -0.74 and a beta of 0.85. The business’s fifty day moving average is $1.60 and its two-hundred day moving average is $1.69. Hookipa Pharma Inc has a 52 week low of $1.25 and a 52 week high of $6.98.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HOOK. SVB Leerink lowered their price objective on Hookipa Pharma from $4.00 to $3.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Truist Financial lowered their price target on Hookipa Pharma from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, August 23rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Hookipa Pharma in a research report on Friday, August 12th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

About Hookipa Pharma

(Get Rating)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Read More

Institutional Ownership by Quarter for Hookipa Pharma (NASDAQ:HOOK)

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.